Clinical trial
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
NCT00041626 is registered in ClinicalTrials.gov with Introgen Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
- Lead sponsor
- Introgen Therapeutics
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.